Lawyers representing opioid makers filed an emergency motion Wednesday night asking the judge in a multistate case to throw out reports from expert witnesses that estimate the companies would need to pay $480 billion in damages. But the judge was
read moreA group of Indian generics makers is starting to take the lead in U.S. generics prescriptions; Chi-Med has filed to list on the Hong Kong Stock Exchange; an explosion at a Qilu Pharma subsidiary killed 10 workers and injured 12.
read moreWhat does it take to steer one of pharma’s biggest whales? As Johnson & Johnson CEO Alex Gorsky told Fortune magazine, six years in the U.S. Army made all the difference. More: Gorsky says military service had 'profound effect' on
read moreWhat used to be a 12 million prescription advantage the “old guard” generics firms held has been overturned, and the “next six” firms—including a slew of Indian drugmakers—now boast a lead of about 2 million as of the end of
read moreRoche’s Tecentriq has scored some important victories lately, including a pair of first-in-class approvals. But in other types of cancer, the Swiss drugmaker has decided to pull the plug. More: Roche throws in the towel on Tecentriq bladder, myeloma trials
read moreBiosimilar drugs aren’t working to cut drug costs, experts say. Instead, it’s time to control prices on biologics after the drugs lose exclusivity. More: Time to give up on biosims, experts say. Price regulations would deliver more savings Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals